 In its Q3 earnings release, Mirati Therapeutics Inc NASDAQ: MRTX posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib plus Merck Co Incs NYSE: MRK Keytruda pembrolizumab in KRAS-mutated first-line non-small cell lung cancer NSCLC. The Company said that a combination of adagrasib and Keytruda posted four partial responses among eight previously untreated patients. 